An pilot study to assess the efficacy of intravenous iron isomaltoside 1000 (Monofer) in the management of anaemia associated with the palliative management of upper gastrointestinal adenocarcinoma

Trial Profile

An pilot study to assess the efficacy of intravenous iron isomaltoside 1000 (Monofer) in the management of anaemia associated with the palliative management of upper gastrointestinal adenocarcinoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Therapeutic Use
  • Acronyms IRON
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Oct 2016 Planned End Date changed from 31 Dec 2015 to 1 Aug 2017.
    • 26 Sep 2015 Accrual to date is 40% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top